Global plasma protein therapeutic market is expected to show a remunerative growth owing to the growing usage of the plasma proteins derived medicines. Introduction of new plasma-derived therapies is the high impact rendering driver for the growth of this market. Rising prevalence of over two hundred life threatening diseases compromising immune or neurological system such as chronic inflammatory demyelinating polyneuropathy (CIPD), ideopathic thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN), and other infectious diseases including hepatitis A&B, Rabies, tetanus and varicella is expected to drive the market growth. Advancement in the technologies involved in efficient and cost effective processes for fractionating the proteins from plasma is supposed to boost the plasma protein therapeutic market. According to the WHO (World Health Organization), more than half of the 108 million global blood donations come from the high income countries, which is the home for 18% of the world’s population. Presence of favorable government initiates for the development of plasma derived medicine and rising awareness regarding the importance of blood donation are the drives for this market.
On the basis of product, plasma protein therapeutic market is segment into coagulation factors, immunoglobulin, alpha-1 proteinase inhibitor, and albumin. In 2013, more than half of the market share was captured by immunoglobulins. Immunoglobulins segment is further divided into intravenous, subcutaneous immunoglobulins, and hyperimmunoglobulins. Owing to the steep rise in the usage of the immunoglobulins in the treatment of rare diseases including genetic diseases, the demand is expected to grow substantially over the next seven years. Increasing prevalence of diseases such as primary and secondary immunodeficiencies, and other infectious diseases such as rabies is expected to drive the demand for the IgG proteins and boost the market growth. Growing prices of the products owing to the sophisticated procedures such as highly selective affinity chromatography is supposed to fuel the market growth during the forecast period. Coagulation factors market is expected to a lucrative growth during the forecast period owing to the increasing applications of the coagulation factors in the rare bleeding conditions such as hepatitis A and B, and Von willebrand’s disease. These conditions have no other promising treatments other that coagulation factors. The segment provides high scope for the new entrants owing to the increasing global demand-supply gap.
Geographically, North America dominated the plasma protein therapeutic market in 2014 with highest volume of blood collection and growing demand for the plasma proteins. According to the data published by the Plasma Protein Therapy Association (PPTA), it is estimated that in 2013, North America acquired more than 40% of the plasma protein therapeutic market. Awareness of people for regular blood donations, presence of commercial organizations with sophisticated technologies for fractionating procedures and high disposable income of the people are the driving forces of the market. According the health department of Government of Australia, average plant capacities of North America region in 2010 was 1,144,000 liters compared to the global average of 475,000 liters. Introduction of recent techniques is anticipated to drive the plasma protein therapeutic market in the future and maintain the dominance of the region. Asia Pacific is expected to witness a significant growth during the forecast period owing to the increasing awareness about blood donations. According to the WHO fact sheet, there has been 78% increase in the rate of blood donation in the South- East Asia during the period of 2004-2012. Growing disposable income of the patients, rising healthcare practitioners awareness, and increasing government initiatives pertaining to the development of plasma protein medicines are expected to fuel the demand of plasma protein products.
Key players of plasma protein therapeutic market include CSL limited, Telecris, Baxter, Grifols, Octapharma, Kedrion, and Chengdu Inst. Many not-for-profit organizations such as Japan Red Cross, LFB group (France), Shanghai Blood Institute, BPL group (UK), and Sanquin are also playing a vital role in plasma protein therapeutic market. The growth of commercial companies may be hampered by the not-for-profit organizations but the current demand supply gap in the market provides great scope for the new entrants during the forecast period.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."